Schwab U.S. Dividend Equity ETF (SCHD) maintains a competitive edge with an ultra-low expense ratio of 0.06%, significantly undercutting many dividend-focused ETFs. The fund currently yields approximately 3.8%, more than triple the yield of the S&P 500 index and notably higher than peers targeting dividend growth. For every $100 invested, investors pay just $0.06 annually in fees, enhancing net income in comparison to funds charging 0.35% or more.

Over the past five years, a $1,000 investment in SCHD would have grown to approximately $1,298 in total return, closely tracking broad dividend-oriented benchmarks. The ETF’s maximum drawdown over the same period was 16.8%, marginally lower than many large-cap dividend funds. Its beta stands at around 0.77 versus the S&P 500, reflecting lower volatility and a smoother ride through market downturns without sacrificing income generation.

SCHD’s holdings encompass 102 large U.S. companies selected from the Dow Jones U.S. Dividend 100 Index based on yield, dividend-payout ratio, cash flow to debt and history of dividend consistency. Key sector allocations include energy (19.3%), consumer staples (18.5%) and healthcare (16.1%). Top individual positions feature major dividend payers such as Bristol-Myers Squibb, Merck & Co. and ConocoPhillips, underscoring a balance between yield and financial stability across industries.

In the third quarter, Charles Schwab Trust Bank reduced its position in SCHD by 43.6%, selling 1.56 million shares and bringing its total holding to just over 2.0 million shares, representing 0.08% of the ETF’s outstanding shares. This divestiture equated to roughly $55 million at prevailing net asset levels. Smaller adjustments by other institutional managers showed modest increases in holdings, suggesting continued interest in SCHD’s income profile despite large single-account rebalancing.